Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and TQB2450 as Adjuvant Therapy in ESCC
NCT05252078Phase 2Recruiting
- Start
- Jun 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib and benmelstobart in Esophageal Squamous Cell Carcinoma (ESCC). Started Jun 2022; status: recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05252078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252078.